ANP32B suppresses B-cell acute lymphoblastic leukemia through activation of PU.1 in mice

Cancer Sci. 2023 Jul;114(7):2882-2894. doi: 10.1111/cas.15822. Epub 2023 May 3.

Abstract

ANP32B, a member of the acidic leucine-rich nuclear phosphoprotein 32 kDa (ANP32) family of proteins, is critical for normal development because its constitutive knockout mice are perinatal lethal. It is also shown that ANP32B acts as a tumor-promoting gene in some kinds of cancer such as breast cancer and chronic myelogenous leukemia. Herein, we observe that ANP32B is lowly expressed in B-cell acute lymphoblastic leukemia (B-ALL) patients, which correlates with poor prognosis. Furthermore, we utilized the N-myc or BCR-ABLp190 -induced B-ALL mouse model to investigate the role of ANP32B in B-ALL development. Intriguingly, conditional deletion of Anp32b in hematopoietic cells significantly promotes leukemogenesis in two B-ALL mouse models. Mechanistically, ANP32B interacts with purine rich box-1 (PU.1) and enhances the transcriptional activity of PU.1 in B-ALL cells. Overexpression of PU.1 dramatically suppresses B-ALL progression, and highly expressed PU.1 significantly reverses the accelerated leukemogenesis in Anp32b-deficient mice. Collectively, our findings identify ANP32B as a suppressor gene and provide novel insight into B-ALL pathogenesis.

Keywords: ANP32B; B-ALL; PU.1; leukemogenesis; tumor suppressor.

MeSH terms

  • Animals
  • Burkitt Lymphoma*
  • Cell Cycle Proteins / metabolism
  • Fusion Proteins, bcr-abl
  • Leukemia, Myeloid*
  • Mice
  • Mice, Knockout
  • Nerve Tissue Proteins / metabolism
  • Nuclear Proteins / genetics
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma* / genetics

Substances

  • Nuclear Proteins
  • Fusion Proteins, bcr-abl
  • Anp32b protein, mouse
  • Nerve Tissue Proteins
  • Cell Cycle Proteins